Gujarat Kidney And Super Speciality shareholding pattern

GKSL

106.31

1.25 (-1.16%)
Last updated on 13 Apr, 2026 | 15:31 IST
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Gujarat Kidney And Super Speciality Shareholding Pattern

  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

71.45%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

4.89%

Domestic Institutional Investors

0.55%

Retail

23.1%

Others

0.01%

Total Promoters
MAR '26
71.45%

Summary

For Year 2026-27, Gujarat Kidney And Super Speciality reports the following shareholding: Total Promoters at 71.45%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 4.89%, Domestic Institutional Investors at 0.55%, and Retail at 23.1%. This breakdown provides a quick snapshot of ownership distribution for Gujarat Kidney And Super Speciality in 2026-27.

Gujarat Kidney And Super Speciality FAQs

As of 04-2026, the promoter shareholding in Gujarat Kidney And Super Speciality stands at 71.45% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Gujarat Kidney And Super Speciality is 4.89% and 0.55% respectively.

The retail shareholding of the Gujarat Kidney And Super Speciality is 23.1%.

Changes in shareholding patterns of Gujarat Kidney And Super Speciality can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Gujarat Kidney And Super Speciality are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost